The utility of EGFR expression in predicting treatment response and DC has been sparsely reported, and a previous study showed that the probability of treatment response was significantly greater in NSCLC on gefitinib and with high EGFR expression compared to those with low expression, although disease control rates were unaffected. Here, EGFR is linked to non-small cell lung carcinoma.